Article
A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.
Clinical pharmacology and therapeutics - 1 May 2003
Watanabe Ichiro, Tomita Aiko, Shimizu Miho, Sugawara Mie, Yasumo Hiroaki, Koishi Ryuta, Takahashi Tohru, Miyoshi Kaoru, Nakamura Kouichi, Izumi Takashi, Matsushita Yasuyuki, Furukawa Hidehiko, Haruyama Hideyuki, Koga Teiichiro
Abstract excerpt
BACKGROUND AND OBJECTIVE: Troglitazone is a 2,4-thiazolidinedione antidiabetic agent with insulin-sensitizing activities. This agent had been used efficiently in a large number of patients but was withdrawn from the market in March 2000 because of its association with idiosyncratic hepatotoxicity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.